License

INTEGRIS Health Provides Notice of Data Privacy Incident

Retrieved on: 
Tuesday, February 6, 2024

OKLAHOMA CITY, Feb. 6, 2024 /PRNewswire/ -- INTEGRIS Health ("INTEGRIS") is making individuals aware of an incident that may affect the privacy of certain information.

Key Points: 
  • OKLAHOMA CITY, Feb. 6, 2024 /PRNewswire/ -- INTEGRIS Health ("INTEGRIS") is making individuals aware of an incident that may affect the privacy of certain information.
  • INTEGRIS Health is providing notice of the event so potentially affected individuals may take steps to better protect their information from misuse, should they feel it appropriate to do so.
  • INTEGRIS Health initiated a thorough review of the potentially accessed data to determine the type of information and to whom it related, and just recently completed that effort.
  • Upon learning of the event, INTEGRIS Health promptly took steps to investigate the full scope of the incident.

DATA INTENSITY NAMED AS FOUNDING PARTNER OF ORACLE'S VENDOR SOFTWARE ASSET MANAGEMENT PROGRAM

Retrieved on: 
Monday, February 5, 2024

COVINGTON, Ky., Feb. 5, 2024 /PRNewswire/ -- Data Intensity, an Oracle Strategic Cloud MSP partner and global leader in Oracle managed cloud services and solutions, announced today its completion of qualifications as a partner in the new Oracle Global Licensing and Advisory Services (GLAS) Software Asset Management program.

Key Points: 
  • The Oracle SAM Program partner designation informs clients that Data Intensity is not only trusted to identify optimization opportunities, but that Data Intensity has qualified Oracle experts to assist in their future use of Oracle products, whether on-premises or in the public cloud.
  • Data Intensity has already achieved the Software Asset Management Expertise for Oracle Database, Oracle Fusion Middleware, and Oracle E-Business Suite in North America, with expansion in the coming weeks into Western Europe and Australia/New Zealand.
  • "LiDestri Foods has relied on Data Intensity for Oracle software asset management services since 2020," said Andrew Finkel, Oracle Development Manager of LiDestri Foods.
  • "Leveraging Data Intensity as our Software Asset Management (SAM) provider has been a great partnership.

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®

Retrieved on: 
Sunday, February 4, 2024

Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.

Key Points: 
  • Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.
  • Upon the expiration of the aforementioned term, the License Agreement may automatically be renewed for ten years as per certain conditions defined in the License Agreement.
  • There is an issued patent that protects the formulation, usage, particle size and manufacturing methods of the Product in China.
  • Velphoro® is a newly approved innovative drug in China in 2023 and has been successfully included in category B of the National Reimbursement Drug List.

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Monday, January 29, 2024

“This grant adds to the breadth of our tumor-targeting therapy patent portfolio, alongside a US patent and Chinese patent in respect of this CAR T technology.

Key Points: 
  • “This grant adds to the breadth of our tumor-targeting therapy patent portfolio, alongside a US patent and Chinese patent in respect of this CAR T technology.
  • The Company’s patent portfolio also includes an exclusively licensed technology which covers an induced pluripotent stem cell (iPSC)-based technology to derive novel synthetic hybrid gamma delta natural killer T cells (γδ NKT cells) for the treatment of various types of cancers.
  • A patent for this proprietary technology has been granted in Japan and China, and this asset is under preclinical development.
  • For more information about the Company's services, latest news, and ongoing initiatives, please visit www.cytomed.sg.

Ranchero Announces Execution of a Definitive Agreement Related to the Disposition of its Santa Daniela Property

Retrieved on: 
Thursday, January 18, 2024

The Company intends to relinquish its interest in the remaining portions of the Santa Daniela property in order to eliminate holding costs (together with the sale of the Licenses, the “Disposition”).

Key Points: 
  • The Company intends to relinquish its interest in the remaining portions of the Santa Daniela property in order to eliminate holding costs (together with the sale of the Licenses, the “Disposition”).
  • For further details of the Disposition, see the Company’s press release dated December 27, 2023.
  • The Disposition is subject to the approval of the TSX Venture Exchange (the “TSXV”) and the shareholders of the Company.
  • In relation to the Disposition, Ranchero has convened a special meeting of its shareholders to be held on February 22, 2024, to seek shareholder approval for the Disposition.

XTM Inc. Provides Further Disclosure on Licensing Agreement

Retrieved on: 
Wednesday, January 24, 2024

XTM, Inc. (“XTM” or the “Company”) (QB: XTMIF / CSE:PAID / FSE:7XT), a Miami and Toronto, Denver and London-based Fintech creator of payment innovations including fully certified Earned Wage Access (“EWA”) through its QRails AnyDay™ product, further to its news release of January 19, 2024 that the Company entered into a USD$3,000,000 licensing agreement on January 19, 2024 (the “Licensing Agreement”) to provide EWA processing for a U.S. entity (the “Customer”), is providing further context to its Licensing Agreement at the request of CIRO.

Key Points: 
  • XTM, Inc. (“XTM” or the “Company”) (QB: XTMIF / CSE:PAID / FSE:7XT), a Miami and Toronto, Denver and London-based Fintech creator of payment innovations including fully certified Earned Wage Access (“EWA”) through its QRails AnyDay™ product, further to its news release of January 19, 2024 that the Company entered into a USD$3,000,000 licensing agreement on January 19, 2024 (the “Licensing Agreement”) to provide EWA processing for a U.S. entity (the “Customer”), is providing further context to its Licensing Agreement at the request of CIRO.
  • As part of this License, the Customer may use the XTM Processing Platform for processing and/or may operate the Processing Platform independently.
  • The Customer shall be responsible for all program management services and banking relationships.
  • The scope and value of such services shall be agreed upon by the parties at the time of the Customer’s request.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Retrieved on: 
Thursday, January 18, 2024

The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next generation, once daily oral product candidate for TRT.

Key Points: 
  • The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next generation, once daily oral product candidate for TRT.
  • Under the agreement, Verity Pharma will be responsible for regulatory and marketing obligations in the U.S. and Canada, and all further development.
  • Lipocine retains all rights to the TLANDO franchise for territories outside the U.S. and Canada, and all rights to non-TRT indications globally.
  • "We are very pleased to enter this license agreement with Verity Pharma.